A recent study shows that in ovarian cancer cells, the combination treatment of the topoisomerase inhibitor and PARP inhibitor (PARPi) is superior to PARP inhibition or topoisomerase inhibition alone [107]. This evidence concerns the gene PARP1 and ovarian carcinoma.